These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 25811348)

  • 1. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
    Su D; Singer EA; Srinivasan R
    Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapeutic strategies for the management of renal cell carcinoma.
    Singer EA; Gupta GN; Srinivasan R
    Curr Opin Oncol; 2012 May; 24(3):284-90. PubMed ID: 22343386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in renal cell carcinoma.
    D'Avella C; Abbosh P; Pal SK; Geynisman DM
    Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prospect of precision therapy for renal cell carcinoma.
    Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
    Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successes and limitations of targeted therapies in renal cell carcinoma.
    Pracht M; Berthold D
    Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma: molecular biology and targeted therapy.
    Su D; Stamatakis L; Singer EA; Srinivasan R
    Curr Opin Oncol; 2014 May; 26(3):321-7. PubMed ID: 24675233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving therapeutic targets in renal cell carcinoma.
    Singer EA; Gupta GN; Marchalik D; Srinivasan R
    Curr Opin Oncol; 2013 May; 25(3):273-80. PubMed ID: 23455028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-clear cell advanced kidney cancer: is there a gold standard?
    Sánchez P; Calvo E; Durán I
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational MET inhibitors to treat Renal cell carcinoma.
    Nandagopal L; Sonpavde GP; Agarwal N
    Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
    [No Abstract]   [Full Text] [Related]  

  • 15. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the epidemiology and biology of renal cortical neoplasms.
    Collins S; McKiernan J; Landman J
    J Endourol; 2006 Dec; 20(12):975-85. PubMed ID: 17206887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.